Arbutus Biopharma Corp Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
Arbutus Biopharma Corp (ABUS) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $1.13 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-05.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2020-05-11
CAD
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month |
|---|---|
| 2012-12-31 | 178.41K CAD 20-F · filed 2013-03-27 |
| 2011-12-31 | 475.57K CAD 20-F · filed 2013-03-27 |
USD
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 6 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 9 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month as first filed |
|---|---|---|---|---|---|
| 2019-12-31 | $1.13M 10-K · filed 2020-03-05 | ||||
| 2019-06-30 | $135.00K 10-Q · filed 2019-08-05 | $270.00K derived: sum of 2 quarters · filed 2020-05-11 | |||
| 2019-03-31 | $135.00K 10-Q · filed 2020-05-11 | ||||
| 2018-12-31 | $1.13M 10-K · filed 2019-03-07 | ||||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $135.00K 10-Q · filed 2018-08-03 | |||
| 2018-03-31 | $135.00K 10-Q · filed 2019-11-06 | ||||
| 2017-12-31 | $1.13M 10-K · filed 2018-03-16 | ||||
| 2015-12-31 | -$5.62M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $4.08M 10-K · filed 2018-03-16 | $9.70M 10-K · filed 2016-03-09 | ||
| 2015-09-30 | $9.70M 10-Q · filed 2015-11-05 | ||||
| 2014-12-31 | $2.46M 10-K · filed 2017-03-22 | $4.08M 10-K · filed 2016-03-09 | |||
| 2013-12-31 | $2.46M 10-K · filed 2016-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |